Close Menu

NEW YORK (GenomeWeb) – OpGen reported after the close of the market on Thursday that its second quarter revenues rose 12 percent year over year thanks to a massive increase in its collaboration revenues.

For the three months ended June 30, the firm reported total revenues of $788,901 compared to revenues of $703,210 a year earlier. Product sales fell 7 percent to $632,525 from $681,127, and laboratory services revenues fell 93 percent to $1,100 from $15,850 in Q2 2017. The firm's Q2 collaborations revenues offset those dips, soaring to $155,276 from $6,233 in the year-ago period.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Researchers are developing a breath test to determine how severe patients' methylmalonic acidemia disease is, FierceBiotech reports.

NPR reports that vaccine developers are working on SARS-CoV-2 vaccines that are easier to store or administer than the current crop.

Reuters reports that France is to recommend that people under 55 who received one dose of AstraZeneca's SARS-CoV-2 vaccine receive a different vaccine for their second dose.